An observational neuroimaging and neurophysiological study investigating the visual pathway in Huntington*s disease.

An observational neuroimaging and neurophysiological study investigating the visual pathway in Huntington*s disease. - Visual pathway in HD.

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON45518

Enrollment

Registered

2017-04-12

Start date

2017-01-16

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hereditary neurodegenerative movement disorder Huntington's disease

Interventions

Huntington's disease

Visual cortex

Visual-Evoked Potentials

Eligibility

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: * Between 18 and 65 years of age at time of visit * Ability to undergo MRI scanning * Written informed consent must be obtained from the participant;If the participant is a manifest HD gene carrier: * Gene positive tested with CAG repeat length of * 36 in the HTT gene * UHDRS-TMS > 5;If the participant is a premanifest HD gene carrier: * Gene positive tested with CAG repeat length of * 36 in the HTT gene * UHDRS-TMS * 5;If the participant is a control subject: * Gene negative tested for HD or without family history of HD * No other known cognitive, neurological or psychiatric disorders

Exclusion criteria

Exclusion criteria: * Impaired primary visual ability (

Design outcomes

Primary

Measure	Time frame
* Group differences and correlations between pre- and manifest HD and healthy controls on the functional and structural MRI outcome parameters. * Correlation between scores on neuropsychological assessments and MRI outcome parameters in all groups. * Differences in VEP outcome measures (amplitudes and latencies) between pre-, manifest HD and healthy controls. * Correlation between VEP outcome measures and outcome parameters of different imaging modalities (e.g. fMRI, DTI and structural MRI).	—

Measure

Time frame

* Group differences and correlations between pre- and manifest HD and healthy controls on the functional and structural MRI outcome parameters. * Correlation between scores on neuropsychological assessments and MRI outcome parameters in all groups. * Differences in VEP outcome measures (amplitudes and latencies) between pre-, manifest HD and healthy controls. * Correlation between VEP outcome measures and outcome parameters of different imaging modalities (e.g. fMRI, DTI and structural MRI).

—

Countries

The Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)